Sodium glucose cotransporter 2 inhibitors, cardiobiomarkers and endothelial dysfunction in patients with chronic cardiac, renal insufficiency and type 2 diabetes

<jats:p>The article assesses influence of sodium glucose cotransporter 2 inhibitors in combined therapy of chronic cardiac insufficiency on the levels of biomarkers of myocardial and renal dysfunction, endothelial function and final nitric oxide metabolites content in patients with stable ischemic heart disease with chronic cardiac insufficiency I-III functional classes and renal insufficiency and with or without type 2 diabetes.</jats:p>